JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Clinical features and management outcomes of hairy cell leukemia in routine clinical practice: a single center retrospective experience
Abstract
Aims: In this study, we aimed to review the clinical and treatment characteristics of hairy cell leukemai (HCL) patients.
Methods: This is a single-center retrospective study conducted at University of Health Sciences, Adana City Hospital, Hematology department between January 2018 and August 2025. The data of 33 patients with the diagnosis of hairy cell leukemia from the database of hospital records were analysed.
Results: First line treatment was cladribine in 27 (81.8%) patients, rituximab-cladribin in 2 (6.1 %) patients, interferon in 1 (3 %) patient and splenectomy in 3 (9.1 %) patients. Thirty one (93.9 %) patients responded to treatment and only 2 (6.1 %) did not. The progression was observed in 8 (25.8 %) of 31 responding patients. The probablity of progression free survival (PFS) at 10 years was 33 %. When the data is analysed according to the age groups of <50 y, 50-60 y and >60 y, the probability of PFS was 42.9 %, 83.3 %, 31.3 %,respectively (p=0.096). Also patients were grouped according to the age <=60 y and >60 y; and the probability of PFS at 10 years were 40.8% v.s 31.3% (p=0.034). All patients were alive at the end of follow up period, so median OS was not reached.
Conclusion: Cladribin was verified to be an effective treatment modality in HCL with high response rate, but low PFS. And the differences in the PFS according to age groups should be reevalated in the era of rituximab-cladribine combination and novel agents.

Keywords : Hairy cell leukemia, purine nucleoside analogs, cladribine, rituximab, prognosis

Download Article
Ethical Statement

<p>This study was approved by the Scientific Researches Ethics Committee of Adana City Training and Research Hospital (Date: 15.01.2026, Decision No: 983).</p>

Informed Consent

<p>This retrospective study used pre-existing anonymized patient data. No additional intervention was performed, and there was no direct patient contact. The study was approved by the Ethics Committee, and the requirement for written informed consent was waived by the ethics committee.</p>

Author Contributions

<p>Concept: ES; Design: ES; Control: ES, DD; Resources: NB; Materials: NB; Data Collection and/or Processing: ES, DD, BA, DYA, ZTK, &Ccedil;&Uuml;, NB; Analysis and/or Interpretation: ES; Literature Review: ES, DD, BA, DYA, ZTK, &Ccedil;&Uuml;, NB; Writing the Article: ES, DD; Critical Review: ES, DD, BA, DYA, ZTK, &Ccedil;&Uuml;, NB.</p>

Conflict of Interest

<p>The authors declare no conflicts of interest related to this study.</p>

Financial Disclosure

<p>The authors received no financial support for the conduct or publication of this research.</p>


1. Falini B, Martino G, Lazzi S. A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. Leukemia. 2023;37(1):18-34. doi:10.1038/s41375-022-01764-1
2. Troussard X, Maître E, Paillassa J. Hairy cell leukemia 2024: update on diagnosis, risk-stratification, and treatment-annual updates in hematological malignancies. Am J Hematol. 2024;99(4):679-696. doi:10.1002/ajh.27240
3. Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129(5):553-560. doi:10.1182/blood-2016-01-689422
4. Mendez-Hernandez A, Moturi K, Hanson V, Andritsos LA. Hairy cell leukemia: where are we in 2023? Curr Oncol Rep. 2023;25(8):833-840. doi:10.1007/s11912-023-01419-z
5. Levy Yurkovski I, Tadmor T. Approach to hairy-cell leukemia in the new therapeutic era with special emphasis on age and comorbidities. Acta Haematol. 2026;149(4):477-486. doi:10.1159/000547722
6. Else M, Dearden CE, Catovsky D. Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract Res Clin Haematol. 2015;28(4):217-229. doi:10.1016/j.beha.2015.09.004
7. Zahid MF, Mehdi MQ, Ali N. Outcome of hairy cell leukemia patients treated with cladribine - a 10-year single-center experience in Pakistan. Hematol Transfus Cell Ther. 2019;41(2):134-138. doi:10.1016/j.htct.2018.08.006
8. Biglari M, Kamranzadeh Foumani H, Bagherian M, Chahardouli B, Ghavamzadeh A. Retrospective evaluation of hairy cell leukemia patients: analysis of a long-term single center data. Int J Hematol Oncol Stem Cell Res. 2022;16(4):209-216. doi:10.18502/ijhoscr.v16i4.10878
9. Broccoli A, Argnani L, Nanni L, et al. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a 30-year experience. Am J Hematol. 2021;96(10):1204-1210. doi:10.1002/ajh.26287
10. Yılmaz F, Atilla D, Akkaş N, et al. Retrospective analysis of hairy cell leukemia patients treated with different modalities as first line: real-life experience over 20 years. Indian J Hematol Blood Transfus. 2019;35(4): 692-698. doi:10.1007/s12288-019-01132-7
11. Dehghani M, Kashkooe A, Namdari N, et al. Long-term follow-up of patients with hairy cell leukemia in the south of Iran. Expert Rev Hematol. 2023;16(4):289-295. doi:10.1080/17474086.2023.2174520
12. Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood. 2014;123(2):177-183. doi:10.1182/blood-2013-06-508754
13. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009; 145(6):733-740. doi:10.1111/j.1365-2141.2009.07668.x
14. Ravandi F, Kreitman RJ, Tiacci E, et al. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12(12):165. doi:10.1038/s41408-022-00760-z
15. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003; 102(3):810-813. doi:10.1182/blood-2003-01-0014
16. Leclerc M, Suarez F, Noël MP, et al. Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases. Ann Hematol. 2015;94(1):89-95. doi:10.1007/s00277-014-2175-0
17. Zenhäusern R, Simcock M, Gratwohl A, et al. Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematologica. 2008;93(9): 1426-1428. doi:10.3324/haematol.11564
18. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer. 2007;110(10):2240-2247. doi:10.1002/cncr.23032
19. Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma. 2011;52 Suppl 2:75-78. doi:10.3109/10428194.2011.568650
20. Ravandi F, O’Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011; 118(14):3818-3823. doi:10.1182/blood-2011-04-351502
21. Chihara D, Kantarjian H, O’Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016;174(5):760-766. doi:10.1111/bjh.14129
22. Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol. 2020;38(14):1527-1538. doi:10.1200/JCO.19.02250
23. Marvin-Peek J, Jen WY, Kantarjian HM, et al. Long-term results of the sequential combination of cladribine and rituximab in hairy cell leukemia. Leuk Lymphoma. 2024;65(9):1325-1334. doi:10.1080/10428194.2024.2349700
24. Hermel DJ, Cheng B, Bhangoo MS, Burian C, Waalen J, Saven A. Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine. Ann Hematol. 2022;101(5):1089-1096. doi:10.1007/s00277-022-04800-3
Article available in :
Volume 4, Issue 4, 2026
Page : 130-134
https://doi.org/10.51271/JCHOR-0096
Article Information
Received : 12 May 2026
Accepted : 20 Jul 2026
Published : 13 Nov 2026
Corresponding Author :

Elif Suyanı: Department of Hematology, Adana City Hospital, Adana, Turkiye

[email protected]
Citation : Suyanı E, Demirtaş D, Aygün B, et al. Clinical features and management outcomes of hairy cell leukemia in routine clinical practice: a single center retrospective experience . J Curr Hematol Oncol Res. 2026;4(4):130-134. doi:10.51271/JCHOR-0096

Read: 19
Download : 3
Cited: 0
_Footer